Busulfex

Busulfex

busulfan

Manufacturer:

Otsuka

Distributor:

Zuellig Pharma

Marketer:

Thai Otsuka
Concise Prescribing Info
Contents
Busulfan
Indications/Uses
In combination w/ cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous leukemia.
Dosage/Direction for Use
Adult 0.8 mg/kg IV via central nervous catheter as a 2-hr infusion 6 hrly for 4 consecutive days (total: 16 doses).
Special Precautions
Myelosuppression. Monitor hematologic status & blood count. History of seizure disorder or head trauma or patients on epileptogenic drugs. Prior radiotherapy or progenitor cell transplant. Pregnancy & lactation. Childn.
Adverse Reactions
Profound myelosuppression including granulocytopenia, thrombocytopenia, anemia. Fever, headache, asthenia, chills, pain, edema, allergic reaction, chest pain, inflammation at inj site, back pain, tachycardia, HTN, thrombosis, vasodilation; GI disturbances; metabolic disorders; insomnia, anxiety, dizziness, depression; resp disorders; rash, pruritus.
Drug Interactions
Clearance decreased by itraconazole & acetaminophen. Clearance increased by phenytoin.
ATC Classification
L01AB01 - busulfan ; Belongs to the class of alkylating agents, alkyl sulfonates. Used in the treatment of cancer.
Presentation/Packing
Form
Busulfex infusion 6 mg/mL
Packing/Price
10 mL x 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in